Targeted In Vivo Labeling of Receptors for Vascular Endothelial Growth Factor

Background A method for identifying tissue experiencing hypoxic stress due to atherosclerotic vascular disease would be clinically useful. Vascular endothelial growth factor‐121 (VEGF121) is an angiogenic protein secreted in response to hypoxia that binds to VEGF receptors overexpressed by ischemic microvasculature. We tested the hypothesis that VEGF receptors could serve as markers for ischemic tissue and hence provide a target for imaging such tissue with radiolabeled human VEGF121. Methods and Results A rabbit model of unilateral hindlimb ischemia was created by femoral artery excision (n=14). Control rabbits (n=5) underwent identical surgery without femoral excision. On postoperative day 10, rabbits were intravenously administered 100 μCi of 111In‐labeled recombinant human VEGF121, and biodistribution studies and planar imaging were conducted at 3, 24, and 48 hours. On postmortem gamma counting, there was greater accumulation of 111In‐labeled VEGF121 in ischemic than in control tissue (P<0.02). Differential uptake of isotope by ischemic muscle was not seen in rabbits injected with 125I‐labeled human serum albumin (n=6). Radioactivity imaged in hindlimb regions of interest was significantly higher in ischemic muscle than in sham‐operated and contralateral nonoperated hindlimb at 3 hours (P<0.02). Immunohistochemical staining confirmed upregulation of VEGF receptors in ischemic skeletal muscle. Conclusions Identification of the ischemic state via targeted radiolabeling of hypoxia‐induced angiogenic receptors is possible. This approach could be useful for monitoring the efficacy of revascularization strategies such as therapeutic angiogenesis. (Circulation. 2003;108:97‐103.)

[1]  T. Visser,et al.  99mTc-MIBI, 99mTc-tetrofosmin and 99mTc-Q12 in vitro and in vivo. , 1998, Nuclear medicine and biology.

[2]  Henry,et al.  Review of Preclinical and Clinical Results with Vascular Endothelial Growth Factors for Therapeutic Angiogenesis. , 2000, Current interventional cardiology reports.

[3]  F. Giordano Angiogenesis: mechanisms, modulation, and targeted imaging. , 1999, Journal of Nuclear Cardiology.

[4]  R. Jue,et al.  Cysteine 116 participates in intermolecular bonding of the human VEGF(121) homodimer. , 2002, Archives of biochemistry and biophysics.

[5]  D. McConnell,et al.  Noninvasive Assessment of Lipid Disposition in Treated and Untreated Atherosclerotic Rabbits , 1989, Pharmaceutical Research.

[6]  M Schwaiger,et al.  Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. , 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  L. Aiello,et al.  Comparative Analysis of Vascular Endothelial Growth Factor Receptors on Retinal and Aortic Vascular Endothelial Cells , 1995, Diabetes.

[8]  L. Brown,et al.  VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. , 1996, The American journal of physiology.

[9]  N. Voelkel,et al.  Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. , 1995, The Journal of clinical investigation.

[10]  F. Blankenberg,et al.  Annexin-V imaging for noninvasive detection of cardiac allograft rejection , 2001, Nature Medicine.

[11]  F Khorasheh,et al.  Application of direct search optimization for pharmacokinetic parameter estimation. , 1999, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[12]  Henry Td,et al.  Review of Preclinical and Clinical Results with Vascular Endothelial Growth Factors for Therapeutic Angiogenesis. , 2000 .

[13]  C. Ng,et al.  Kinetic analysis of technetium-99m-labeled nitroimidazole (BMS-181321) as a tracer of myocardial hypoxia. , 1995, Circulation.

[14]  K. Lachapelle,et al.  A persistent hindlimb ischemia model in the rabbit. , 1994, Journal of investigative surgery : the official journal of the Academy of Surgical Research.

[15]  J. Isner,et al.  Therapeutic Angiogenesis for Coronary Artery Disease , 2002, Annals of Internal Medicine.

[16]  J. Abraham,et al.  Myocardial Contrast Echocardiography Can Be Used to Assess the Microvascular Response to Vascular Endothelial Growth Factor-121 , 2002, Circulation.

[17]  B. Keyt,et al.  Hypoxia-induced paracrine regulation of vascular endothelial growth factor receptor expression. , 1996, The Journal of clinical investigation.

[18]  E. Keshet,et al.  Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis , 1992, Nature.

[19]  B Z Levi,et al.  VEGF121, a vascular endothelial growth factor (VEGF) isoform lacking heparin binding ability, requires cell-surface heparan sulfates for efficient binding to the VEGF receptors of human melanoma cells , 1995, The Journal of Biological Chemistry.

[20]  F. Clubb,et al.  Major histocompatibility complex class II antigen expression in rejecting cardiac allografts: detection using in vivo imaging with radiolabeled monoclonal antibody. , 1997, Circulation.

[21]  A. Sinusas The potential for myocardial imaging with hypoxia markers. , 1999, Seminars in nuclear medicine.

[22]  J. Narula,et al.  Noninvasive detection of atherosclerotic lesions by 99mTc-based immunoscintigraphic targeting of proliferating smooth muscle cells. , 1997, Chest.

[23]  A. Fischman,et al.  Rapid noninvasive detection of experimental atherosclerotic lesions with novel 99mTc-labeled diadenosine tetraphosphates. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Lees,et al.  External Imaging of Atherosclerosis in Rabbits Using an 123I‐Labeled Synthetic Peptide Fragment , 1993, Journal of clinical pharmacology.

[25]  T. Mulnix,et al.  Myocardial kinetics of a putative hypoxic tissue marker, 99mTc-labeled nitroimidazole (BMS-181321), after regional ischemia and reperfusion. , 1995, Circulation.

[26]  J. Witztum,et al.  In vivo uptake of radiolabeled MDA2, an oxidation-specific monoclonal antibody, provides an accurate measure of atherosclerotic lesions rich in oxidized LDL and is highly sensitive to their regression. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[27]  S J Goldsmith,et al.  Receptor imaging: competitive or complementary to antibody imaging? , 1997, Seminars in nuclear medicine.

[28]  F. Sheehan,et al.  Scintigraphic quantification of myocardial necrosis in patients after intravenous injection of myosin-specific antibody. , 1986, Circulation.

[29]  N. Ferrara,et al.  The biology of vascular endothelial growth factor. , 1997, Endocrine reviews.

[30]  Matthew A. Williams,et al.  Synthesis of enantiomerically pure diethylenetriaminepentaacetic acid analogs. L-Phenylalanine as the educt for substitution at the central acetic acid , 1993 .